{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T06:09:35Z","timestamp":1769753375935,"version":"3.49.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"none"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Patients with WHO grade 2 and 3 isocitrate dehydrogenase mutation (IDHmt) gliomas commonly receive temozolomide (TMZ), with or without radiation therapy, as initial therapy. At progression, TMZ is sometimes reinstated despite a paucity of data on effectiveness.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We reviewed imaging outcomes of patients with WHO 2016 grade II\/III IDHmt gliomas re-treated with TMZ at first progression between 2007 and 2019. Tumor growth rates were calculated over the year preceding re-treatment and throughout the re-treatment period, ranging from 3 to 41 months. RANO criteria were utilized to assess TMZ response rate.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>15 subjects included six grade II, five grade III oligodendrogliomas, one grade II and three grade III astrocytomas. Median time between completion of the first TMZ course and initiation of re-treatment was 47 months. Median progression-free survival with TMZ re-treatment was 27.4 months and median overall survival was 47.8 months. Mean rate of tumor growth by bidimensional product increased from 0.29 cm<jats:sup>2<\/jats:sup> \/month, in the year prior to first tumor progression, to 0.47 cm<jats:sup>2<\/jats:sup>\/month during re-treatment, ranging from 3 to 41 months, with monotherapy TMZ. Volumetric mean rate of tumor growth was 1.12\u00a0cc\/month in the year prior to first tumor progression versus 1.29\u00a0cc\/month during TMZ re-treatment. Five patients experienced tumor growth rate reduction, of whom 3 patients experienced tumor shrinkage as measured by 2D; 2 of these 3 patients also experienced tumor shrinkage as measured by 3D. There was no radiographic response by RANO criteria.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>These findings suggest previously treated, progressive IDHmt gliomas are generally resistant to TMZ, underscoring the need for alternative approaches.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s11060-025-05087-w","type":"journal-article","created":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T15:35:05Z","timestamp":1755704105000},"page":"1147-1154","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effects of re-challenge with temozolomide in grade 2\/3 IDH mutant gliomas at first progression"],"prefix":"10.1007","volume":"175","author":[{"given":"Lalanthica V.","family":"Yogendran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhinav","family":"Kareddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salma O.","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zachary","family":"Scharf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Patrie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sohil H.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1896-2502","authenticated-orcid":false,"given":"David","family":"Schiff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,20]]},"reference":[{"issue":"12 Suppl 2","key":"5087_CR1","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/noad149","volume":"25","author":"QT Ostrom","year":"2023","unstructured":"Ostrom QT, Price M, Neff C et al (2023) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the united States in 2016\u20132020. Neuro Oncol 25(12 Suppl 2):iv1\u2013iv99","journal-title":"Neuro Oncol"},{"key":"5087_CR2","doi-asserted-by":"crossref","unstructured":"Kayabolen A, Yilmaz E, Bagci-Onder T (2021) IDH Mutations in Glioma: Double-Edged Sword in Clinical Applications? Biomedicines 9(7):799","DOI":"10.3390\/biomedicines9070799"},{"issue":"5","key":"5087_CR3","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s11910-013-0345-4","volume":"13","author":"AL Cohen","year":"2013","unstructured":"Cohen AL, Holmen SL, Colman H (2013) IDH1 and IDH2 mutations in gliomas. Curr Neurol Neurosci Rep 13(5):345","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"3","key":"5087_CR4","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.3892\/ol.2017.6543","volume":"14","author":"J Spitaels","year":"2017","unstructured":"Spitaels J, Devriendt D, Sadeghi N et al (2017) Management of supratentorial recurrent low-grade glioma: A multidisciplinary experience in 35 adult patients. Oncol Lett 14(3):2789\u20132795","journal-title":"Oncol Lett"},{"issue":"5","key":"5087_CR5","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1093\/neuonc\/noz016","volume":"21","author":"JJ Miller","year":"2019","unstructured":"Miller JJ, Loebel F, Juratli TA et al (2019) Accelerated progression of IDH mutant glioma after first recurrence. Neuro Oncol 21(5):669\u2013677","journal-title":"Neuro Oncol"},{"issue":"10","key":"5087_CR6","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1001\/jamaneurol.2014.1205","volume":"71","author":"Z Turkalp","year":"2014","unstructured":"Turkalp Z, Karamchandani J, Das S (2014) IDH mutation in glioma: new insights and promises for the future. JAMA Neurol 71(10):1319\u20131325","journal-title":"JAMA Neurol"},{"issue":"5","key":"5087_CR7","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1002\/cncr.23677","volume":"113","author":"MC Chamberlain","year":"2008","unstructured":"Chamberlain MC (2008) Temozolomide for recurrent low-grade spinal cord gliomas in adults. Cancer 113(5):1019\u20131024","journal-title":"Cancer"},{"issue":"3","key":"5087_CR8","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s11060-015-1910-2","volume":"125","author":"BV Nahed","year":"2015","unstructured":"Nahed BV, Redjal N, Brat DJ et al (2015) Management of patients with recurrence of diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline. J Neurooncol 125(3):609\u2013630","journal-title":"J Neurooncol"},{"issue":"4","key":"5087_CR9","first-page":"513","volume":"19","author":"R Ortiz","year":"2021","unstructured":"Ortiz R, Perazzoli G, Cabeza L et al (2021) Temozolomide: an updated overview of resistance mechanisms, nanotechnology advances and clinical applications. Curr Neuropharmacol 19(4):513\u2013537","journal-title":"Curr Neuropharmacol"},{"issue":"Suppl 8","key":"5087_CR10","doi-asserted-by":"publisher","first-page":"viii1","DOI":"10.1093\/neuonc\/noae165.1303","volume":"26","author":"D Schiff","year":"2024","unstructured":"Schiff D, O\u2019Neill A, Brown P et al (2024) Progression-Free and overall survival results of ECOG-ACRIN E3F05: A phase 3 intergroup trial of radiation\u2009\u00b1\u2009temozolomide for grade II gliomas. Neuro Oncol 26(Suppl 8):viii1\u2013viii3","journal-title":"Neuro Oncol"},{"issue":"11","key":"5087_CR11","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/S1470-2045(16)30313-8","volume":"17","author":"BG Baumert","year":"2016","unstructured":"Baumert BG, Hegi ME, van den Bent MJ et al (2016) Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033\u201326033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol 17(11):1521\u20131532","journal-title":"Lancet Oncol"},{"issue":"4","key":"5087_CR12","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.ijrobp.2020.03.027","volume":"107","author":"BJ Fisher","year":"2020","unstructured":"Fisher BJ, Pugh SL, Macdonald DR et al (2020) Phase 2 study of a Temozolomide-Based chemoradiation therapy regimen for High-Risk, Low-Grade gliomas: Long-Term results of radiation therapy oncology group 0424. Int J Radiat Oncol Biol Phys 107(4):720\u2013725","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"5087_CR13","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S1470-2045(21)00090-5","volume":"22","author":"MJ van den Bent","year":"2021","unstructured":"van den Bent MJ, Tesileanu CMS, Wick W et al (2021) Adjuvant and concurrent Temozolomide for 1p\/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053\u2013\u200922054): second interim analysis of a randomised, open-label, phase 3 study. Lancet Oncol 22(6):813\u2013823","journal-title":"Lancet Oncol"},{"issue":"7","key":"5087_CR14","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1056\/NEJMoa2304194","volume":"389","author":"IK Mellinghoff","year":"2023","unstructured":"Mellinghoff IK, van den Bent MJ, Blumental DT et al (2023) Vorasidenib in IDH1-or IDH2-Mutant Low-Grade glioma. N Engl J Med 389(7):589\u2013601","journal-title":"N Engl J Med"},{"issue":"11","key":"5087_CR15","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1002\/cncr.21564","volume":"104","author":"E Franceschi","year":"2005","unstructured":"Franceschi E, Omuro AM, Lassman AB, Demopoulos A, Nolan C, Abrey LE (2005) Salvage Temozolomide for prior Temozolomide responders. Cancer 104(11):2473\u20132476","journal-title":"Cancer"},{"issue":"3","key":"5087_CR16","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s11060-014-1589-9","volume":"120","author":"G Reyes-Botero","year":"2014","unstructured":"Reyes-Botero G, Laigle-Donadey F, Mokhtari K, Martin-Duverneuil N, Delattre JY (2014) Temozolomide after radiotherapy in recurrent low grade diffuse brainstem glioma in adults. J Neurooncol 120(3):581\u2013586","journal-title":"J Neurooncol"},{"issue":"2","key":"5087_CR17","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s11060-008-9600-y","volume":"89","author":"A Tosoni","year":"2008","unstructured":"Tosoni A, Franceschi E, Ermani M, Bertorelle R, Bonaldi L et al (2008) Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas. J Neurooncol 89(2):179\u2013185","journal-title":"J Neurooncol"},{"key":"5087_CR18","doi-asserted-by":"publisher","first-page":"601175","DOI":"10.3389\/fonc.2020.601175","volume":"10","author":"J Ge","year":"2021","unstructured":"Ge J, Li C, Xue F et al (2021) Apatinib plus temozolomide: an effective salvage treatment for recurrent glioblastoma. Front Oncol 10:601175","journal-title":"Front Oncol"},{"key":"5087_CR19","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1080\/01621459.1997.10474049","volume":"92","author":"JA Wellner","year":"1997","unstructured":"Wellner JA, Zhan Y (1997) A hybrid algorithm for computation of the nonparametric maximum likelihood estimator from censored data. J Am Stat Assoc 92:945\u2013959","journal-title":"J Am Stat Assoc"},{"key":"5087_CR20","volume-title":"Counting processes and survival analysis","author":"TR Fleming","year":"1991","unstructured":"Fleming TR, Harrington P (1991) Counting processes and survival analysis. Wiley, New York"},{"issue":"11","key":"5087_CR21","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1093\/neuonc\/noab081","volume":"23","author":"Y Yu","year":"2021","unstructured":"Yu Y, Villanueva-Meyer J, Grimmer MR et al (2021) Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas. Neuro Oncol 23(11):1872\u20131884","journal-title":"Neuro Oncol"},{"issue":"1","key":"5087_CR22","first-page":"vdae105","volume":"6","author":"T Haynes","year":"2024","unstructured":"Haynes T, Gilbert MR, Breen K, Yang C (2024) Pathways to hypermutation in high-grade gliomas: mechanisms, syndromes, and opportunities for immunotherapy. Neurooncol Adv 6(1):vdae105","journal-title":"Neurooncol Adv"},{"issue":"5","key":"5087_CR23","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1212\/01.WNL.0000137049.65631.DB","volume":"63","author":"VH Triebels","year":"2004","unstructured":"Triebels VH, Taphoorn MJ, Brandes AA et al (2004) Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas. Neurology 63(5):904\u2013906","journal-title":"Neurology"},{"issue":"2","key":"5087_CR24","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s11060-014-1714-9","volume":"122","author":"MC Chamberlain","year":"2015","unstructured":"Chamberlain MC (2015) Salvage therapy with lomustine for Temozolomide refractory recurrent anaplastic astrocytoma: a retrospective study. J Neurooncol 122(2):329\u2013338","journal-title":"J Neurooncol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05087-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-025-05087-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05087-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T07:12:21Z","timestamp":1759993941000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-025-05087-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,20]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["5087"],"URL":"https:\/\/doi.org\/10.1007\/s11060-025-05087-w","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,20]]},"assertion":[{"value":"29 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}